SPV TIMSER

Timser Group (SPV TIMSER) is a Mexican biotechnology company specializing in innovative healthcare solutions for women, particularly in the field of oncology and infectious diseases. The company is widely recognized for developing Preventix, a non-invasive, blood-based diagnostic test that utilizes a patented three-protein biomarker panel for the early detection of cervical cancer and precancerous lesions. In addition to its diagnostic portfolio, Timser is advancing therapeutic candidates such as ATSOvid, an inhaled small molecule treatment containing glycyrrhizin and enoxolone, which has completed Phase 2 clinical trials for respiratory viral infections including COVID-19. The company also develops ATSOlona, a treatment targeting HPV-related lesions and cervical cancer. Timser maintains strategic partnerships with organizations like the Aptamer Group to integrate advanced Optimer binders into its diagnostic platforms. Headquartered in Mexico City, the company is supported by impact investors and academic collaborations with institutions like UNAM.